Quel objectif de LDL en prévention secondaire

Quel objectif de LDL en prevention secondaire ? M. John Chapman, Endocrinology-Metabolism Service, Pitie-Salpetriere University Hospital, Sorbonne University, Paris. An extensive data base derived from randomised, placebo-controlled intervention trials in dyslipidemic subjects has established that targeted lowering of LDL-cholesterol reduces the incidence of cardiovascular events, including ischemic stroke, in secondary prevention. Recent findings from the FOURIER and ODYSSEY OUTCOMES trials in secondary prevention patients involving use of PCSK9 inhibitors as add-on therapy to statin treatment have demonstrated a continuum of clinical benefit to LDL-C levels well below 50 mg/dL (1.3 mmol/L). As a consequence, the 2019 ESC/EAS guidelines for cholesterol management in secondary prevention propose an LDL-C goal of